20:01 , Nov 2, 2018 |  BC Week In Review  |  Company News

Takeda proposes divestment of Shire GI candidate, announces loans

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it completes its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). The move...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
19:58 , Aug 4, 2017 |  BC Week In Review  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
23:20 , Aug 3, 2017 |  BC Extra  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
23:06 , Nov 3, 2016 |  BC Innovations  |  Targets & Mechanisms

Going against the gut

While patients might have a long wait for an HIV vaccine, several groups are working on the next best thing: strategies that boost patient immune systems to control the infection without the need for daily...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

Pfizer, Shire deal

Shire licensed worldwide rights to Pfizer’s PF-00547659 . The anti-human mucosal addressin cell adhesion molecule 1 ( MAdCAM-1 ) mAb has completed Phase II testing to treat ulcerative colitis (UC) and Crohn’s disease. Shire said...
00:23 , Jun 15, 2016 |  BC Extra  |  Company News

Shire licenses IBD biologic from Pfizer

Pfizer Inc. (NYSE:PFE) granted Shire plc (LSE:SHP; NASDAQ:SHPG) global rights to inflammatory bowel disease (IBD) candidate PF-00547659 . Deal terms were not disclosed. The mAb targeting mucosal vascular addressing cell adhesion molecule 1 ( MAdCAM-1...
08:00 , Dec 4, 2014 |  BC Innovations  |  Strategy

Merck Encycles through Canada

The first disclosed grant under Merck & Co. Inc. 's Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin α4b7 inhibitors for inflammatory bowel disease....
07:00 , Sep 18, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Chris Cain, Associate Editor, and Kai-Jye Lou, Senior Writer RNA sequencing standardized The FDA has convened a consortium to review the status of RNA sequencing for drug development and outline hurdles for incorporating the technology...
08:00 , Jan 30, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Amgen's IBD gene hunt Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an...